Justin Chakma - 02 Jan 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
02 Jan 2024
Net transactions value
$0
Form type
4
Filing time
04 Jan 2024, 16:41:27 UTC
Previous filing
05 Jan 2023
Next filing
27 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +350,000 $0.000000 350,000 02 Jan 2024 Common Stock 350,000 $5.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.